

Universal Biosensors, Inc.  
ARBN 121 559 993

1 Corporate Avenue  
Rowville Victoria 3178  
Australia

Telephone +61 3 9213 9000  
Facsimile +61 3 9213 9099  
Email [info@universalbiosensors.com](mailto:info@universalbiosensors.com)  
[www.universalbiosensors.com](http://www.universalbiosensors.com)



3 May 2023

**UBI launches PETRACKR® Diabetes product for dogs and cats.  
UBI signs multiple distribution deals and makes “first sales” in USA and Canada.**

Universal Biosensors, Inc. (ASX: UBI) is delighted to announce it has today launched its PETRACKR blood glucose monitoring product for dogs and cats with diabetes globally.

To coincide with the launch, UBI announces it has signed three distribution partnerships in the United States of America and Canada and received initial purchase orders of circa \$280,000. First year sales value from these three deals is expected to exceed \$2 million with sales growth expected in the following years.

10,000 PETRACKR analysers and 375,000 diabetes test strips have been delivered or are in transit to UBI warehouses in the USA and Europe. Stock to fill “first orders” for the newly acquired UBI customers in the United States of America and Canada will be delivered during May.

UBI expect to announce first sales to additional distribution partners over the coming 6-8 weeks with multiple deals in the USA, Europe and Asia Pacific in the final stages of negotiation and documentation.

Mr John Sharman, CEO of UBI said; “We are delighted with the launch of our PETRACKR blood glucose monitoring product. Blood glucose monitoring in companion animals (dogs and cats) with diabetes is a growing market and is estimated to be \$270 million p.a. Glucose test strip volumes are estimated to be approximately 150 million p.a. and device volumes in the order of 1 million p.a. The market is growing at 12% p.a. largely because of increasing pet adoption and increasing rates of obesity in pets globally”.

Mr Sharman said; “UBI is confident that our PETRACKR product, (which leverages UBI’s human blood glucose monitoring pedigree and technology) will be a better alternative for customers in terms of price, accuracy, latest technology, user App and overall performance compared to the current products available in the market. We expect PETRACKR to win significant market share over time.”

For further information please refer to the PETRACKR website (<https://www.universalbiosensors.com/products/petrackr/>).

**End**



Enquiries:  
John Sharman  
Chief Executive Officer  
+61 (0) 414 440 680

*Announcement authorized by the Board of Directors of Universal Biosensors, Inc.*

#### **About Universal Biosensors**

Universal Biosensors, founded in 2001, specialises in the design and development of electrochemical cells (strips) used in conjunction with point of use devices that are used in various industries such as healthcare (point of care), wine, food, and agriculture. UBI's ambition is to build a multi product stable of biosensors in large markets which generate ongoing revenue streams. For additional information regarding Universal Biosensors, Inc., refer to: <http://www.universalbiosensors.com>.

#### **Forward-Looking Statements**

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the US Securities Exchange Act of 1934. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposals outlined in this release will occur, and the terms of any such proposal are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.